3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Plasmacytoma
1
Nasopharyngeal Carcinoma
1
Meningeal Carcinomatosis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Glioma
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
40
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioblastoma
×
Immunotherapy, Adoptive
×
90 days
×
Clear all
No trials found.